| # | Title | Journal | Year | Citations |
|---|
| 1 | Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab | Cell | 2017 | 1,515 |
| 2 | The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee | Blood | 2022 | 512 |
| 3 | Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma | Blood | 2018 | 335 |
| 4 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2019 | 254 |
| 5 | Plasma Ceramides, Mediterranean Diet, and Incident Cardiovascular Disease in the PREDIMED Trial (Prevención con Dieta Mediterránea) | Circulation | 2017 | 227 |
| 6 | Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome | JAMA Neurology | 2020 | 171 |
| 7 | Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial | Lancet Haematology,the | 2019 | 168 |
| 8 | Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study | Leukemia | 2020 | 163 |
| 9 | The clinical characterization of the patient with primary psychosis aimed at personalization of management | World Psychiatry | 2021 | 153 |
| 10 | Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma | Blood | 2016 | 144 |
| 11 | Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients | Blood | 2016 | 129 |
| 12 | Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients | Molecular Therapy | 2016 | 122 |
| 13 | Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment | Blood | 2016 | 121 |
| 14 | Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma | Blood | 2019 | 110 |
| 15 | Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) | Leukemia | 2020 | 109 |
| 16 | Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model | Cancer Immunology, Immunotherapy | 2019 | 100 |
| 17 | Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma | Blood | 2019 | 94 |
| 18 | Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance | Blood | 2016 | 81 |
| 19 | The cellular origin and malignant transformation of Waldenström macroglobulinemia | Blood | 2015 | 80 |
| 20 | NLRP3 Inflammasome: A Possible Link Between Obesity-Associated Low-Grade Chronic Inflammation and Colorectal Cancer Development | Frontiers in Immunology | 2018 | 77 |
| 21 | Structural Studies of Lipopolysaccharide-defective Mutants from Brucella melitensis Identify a Core Oligosaccharide Critical in Virulence | Journal of Biological Chemistry | 2016 | 76 |
| 22 | Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development | Journal of Hematology and Oncology | 2016 | 72 |
| 23 | Guidelines for determination of the number of prior lines of therapy in multiple myeloma | Blood | 2015 | 71 |
| 24 | Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis | Blood | 2016 | 68 |
| 25 | Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE | Blood | 2022 | 64 |
| 26 | Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group | Blood Cancer Journal | 2018 | 59 |
| 27 | The experience of living with advanced-stage cancer: a thematic synthesis of the literature | European Journal of Cancer Care | 2016 | 54 |
| 28 | PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas | Blood | 2019 | 54 |
| 29 | Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality | Blood | 2015 | 50 |
| 30 | Preoperative Circulating Succinate Levels as a Biomarker for Diabetes Remission After Bariatric Surgery | Diabetes Care | 2019 | 47 |
| 31 | Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group | Lancet Haematology,the | 2022 | 44 |
| 32 | Circulating Betatrophin Levels Are Increased in Anorexia and Decreased in Morbidly Obese Women | Journal of Clinical Endocrinology and Metabolism | 2015 | 42 |
| 33 | Is immunotherapy here to stay in multiple myeloma? | Haematologica | 2017 | 42 |
| 34 | Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | Frontiers in Immunology | 2021 | 42 |
| 35 | IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination | Oncotarget | 2017 | 41 |
| 36 | Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT | Blood Advances | 2017 | 40 |
| 37 | The Role of Circulating Biomarkers in Peripheral Arterial Disease | International Journal of Molecular Sciences | 2021 | 40 |
| 38 | Kefir and Intestinal Microbiota Modulation: Implications in Human Health | Frontiers in Nutrition | 2021 | 39 |
| 39 | Altered Concentrations in Dyslipidemia Evidence a Role for ANGPTL8/Betatrophin in Lipid Metabolism in Humans | Journal of Clinical Endocrinology and Metabolism | 2016 | 37 |
| 40 | Adeno-Associated Viral Vectors Serotype 8 for Cell-Specific Delivery of Therapeutic Genes in the Central Nervous System | Frontiers in Neuroanatomy | 2017 | 36 |
| 41 | Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis | Blood | 2016 | 34 |
| 42 | A Systematic Evaluation of the Two-Component Systems Network Reveals That ArlRS Is a Key Regulator of Catheter Colonization by Staphylococcus aureus | Frontiers in Microbiology | 2018 | 34 |
| 43 | Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD) | Journal of Extracellular Vesicles | 2020 | 34 |
| 44 | Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma | Blood Advances | 2022 | 31 |
| 45 | mPGES-1 (Microsomal Prostaglandin E Synthase-1) Mediates Vascular Dysfunction in Hypertension Through Oxidative Stress | Hypertension | 2018 | 29 |
| 46 | Screen Time and Parents’ Education Level Are Associated with Poor Adherence to the Mediterranean Diet in Spanish Children and Adolescents: The PASOS Study | Journal of Clinical Medicine | 2021 | 29 |
| 47 | van Manen's phenomenology of practice: How can it contribute to nursing? | Nursing Inquiry | 2019 | 28 |
| 48 | Differential profile of activated regulatory T cell subsets and microRNAs in tolerant liver transplant recipients | Liver Transplantation | 2017 | 25 |
| 49 | Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study | Journal of Neuro-Oncology | 2020 | 25 |
| 50 | Cereblon enhancer methylation and IMiD resistance in multiple myeloma | Blood | 2021 | 25 |
